FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059581639> ?p ?o ?g. }

• W2059581639 endingPage "2596.e3" @default.
• W2059581639 startingPage "2581" @default.
• W2059581639 abstract "Purpose The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation. Methods This Phase II study was conducted by using a randomized, multicenter, double-blind, placebo-controlled, 3 × 3 factorial design. After a 2-week placebo run-in period, eligible hypertensive patients (with a sitting diastolic blood pressure [SiDBP] between 90 and 114 mm Hg) were randomized to treatment. They received single or combined administration of fimasartan at 3 doses (0, 30, and 60 mg) and amlodipine at 3 doses (0, 5, and 10 mg) for 8 weeks. The primary efficacy end point was the change in SiDBP from baseline and at week 8; secondary end points included the change in SiDBP from baseline and at week 4 and the changes in sitting systolic blood pressure from baseline and at weeks 4 and 8. Treatment-emergent adverse events (AEs) were also assessed. Findings 420 Korean patients with mild to moderate hypertension were randomly allocated to the 9 groups. Mean (SD) SiDBP changes in each group after 8 weeks were as follows: placebo, –6.0 (8.5) mm Hg; amlodipine 5 mg, –10.6 (9.2) mm Hg; amlodipine 10 mg, –15.9 (7.2) mm Hg; fimasartan 30 mg, –10.1 (9.1) mm Hg; fimasartan 60 mg, –13.0 (10.0) mm Hg; fimasartan 30 mg/amlodipine 5 mg, –16.2 (8.5) mm Hg; fimasartan 30 mg/amlodipine 10 mg, –19.5 (7.5) mm Hg; fimasartan 60 mg/amlodipine 5 mg, –16.6 (6.9) mm Hg; and fimasartan 60 mg/amlodipine 10 mg, –21.5 (8.3) mm Hg. All treatment groups produced significantly greater reductions in blood pressure compared with the placebo group. In addition, all combination treatment groups had superior reductions in blood pressure compared with the monotherapy groups. In the combination treatment groups, doubling fimasartan dose in the given dose of amlodipine did not show further BP reduction, whereas doubling amlodipine dose showed significantly further BP reduction in the given dose of fimasartan. During the study period, 75 (17.9%) of 419 patients experienced 110 AEs. Ninety-five AEs were mild, 9 were moderate, and 6 were severe in intensity. Eight patients discontinued the study due to AEs. There was no significant difference in incidence of AEs among groups (P = 0.0884). The most common AE was headache (12 patients [2.9%]), followed by dizziness (11 patients [2.6%]) and elevated blood creatine phosphokinase levels (6 patients [1.4%]). Implications Fimasartan combined with amlodipine produced superior blood pressure reductions and low levels of AEs compared with either monotherapy. Therefore, a single-pill combination with fimasartan 60 mg/amlodipine 10 mg will be developed. ClinicalTrials.gov: NCT01518998." @default.
• W2059581639 created "2016-06-24" @default.
• W2059581639 creator A5005178090 @default.
• W2059581639 creator A5007158625 @default.
• W2059581639 creator A5008317220 @default.
• W2059581639 creator A5015339355 @default.
• W2059581639 creator A5015498389 @default.
• W2059581639 creator A5016608182 @default.
• W2059581639 creator A5017717068 @default.
• W2059581639 creator A5018800406 @default.
• W2059581639 creator A5023022774 @default.
• W2059581639 creator A5023141443 @default.
• W2059581639 creator A5023696975 @default.
• W2059581639 creator A5024932707 @default.
• W2059581639 creator A5029625046 @default.
• W2059581639 creator A5031663382 @default.
• W2059581639 creator A5034147174 @default.
• W2059581639 creator A5037630452 @default.
• W2059581639 creator A5039502897 @default.
• W2059581639 creator A5040155349 @default.
• W2059581639 creator A5040663056 @default.
• W2059581639 creator A5044738299 @default.
• W2059581639 creator A5046308082 @default.
• W2059581639 creator A5053631633 @default.
• W2059581639 creator A5065796888 @default.
• W2059581639 creator A5080149524 @default.
• W2059581639 creator A5080532811 @default.
• W2059581639 creator A5085895771 @default.
• W2059581639 creator A5086211005 @default.
• W2059581639 date "2015-11-01" @default.
• W2059581639 modified "2023-10-16" @default.
• W2059581639 title "A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension" @default.
• W2059581639 cites W1887516134 @default.
• W2059581639 cites W1899029424 @default.
• W2059581639 cites W1966190328 @default.
• W2059581639 cites W1973605558 @default.
• W2059581639 cites W1974719260 @default.
• W2059581639 cites W1982002364 @default.
• W2059581639 cites W1985259248 @default.
• W2059581639 cites W2009820178 @default.
• W2059581639 cites W2025183648 @default.
• W2059581639 cites W2025811675 @default.
• W2059581639 cites W2035389341 @default.
• W2059581639 cites W2054613686 @default.
• W2059581639 cites W2058188111 @default.
• W2059581639 cites W2066035059 @default.
• W2059581639 cites W2068647218 @default.
• W2059581639 cites W2070382772 @default.
• W2059581639 cites W2077978072 @default.
• W2059581639 cites W2087285082 @default.
• W2059581639 cites W2090040452 @default.
• W2059581639 cites W2091720550 @default.
• W2059581639 cites W2091765464 @default.
• W2059581639 cites W2101659333 @default.
• W2059581639 cites W2110880027 @default.
• W2059581639 cites W2112754490 @default.
• W2059581639 cites W2120927962 @default.
• W2059581639 cites W2167557672 @default.
• W2059581639 cites W2172032309 @default.
• W2059581639 doi "https://doi.org/10.1016/j.clinthera.2015.02.019" @default.
• W2059581639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25850881" @default.
• W2059581639 hasPublicationYear "2015" @default.
• W2059581639 type Work @default.
• W2059581639 sameAs 2059581639 @default.
• W2059581639 citedByCount "12" @default.
• W2059581639 countsByYear W20595816392016 @default.
• W2059581639 countsByYear W20595816392017 @default.
• W2059581639 countsByYear W20595816392018 @default.
• W2059581639 countsByYear W20595816392019 @default.
• W2059581639 countsByYear W20595816392022 @default.
• W2059581639 countsByYear W20595816392023 @default.
• W2059581639 crossrefType "journal-article" @default.
• W2059581639 hasAuthorship W2059581639A5005178090 @default.
• W2059581639 hasAuthorship W2059581639A5007158625 @default.
• W2059581639 hasAuthorship W2059581639A5008317220 @default.
• W2059581639 hasAuthorship W2059581639A5015339355 @default.
• W2059581639 hasAuthorship W2059581639A5015498389 @default.
• W2059581639 hasAuthorship W2059581639A5016608182 @default.
• W2059581639 hasAuthorship W2059581639A5017717068 @default.
• W2059581639 hasAuthorship W2059581639A5018800406 @default.
• W2059581639 hasAuthorship W2059581639A5023022774 @default.
• W2059581639 hasAuthorship W2059581639A5023141443 @default.
• W2059581639 hasAuthorship W2059581639A5023696975 @default.
• W2059581639 hasAuthorship W2059581639A5024932707 @default.
• W2059581639 hasAuthorship W2059581639A5029625046 @default.
• W2059581639 hasAuthorship W2059581639A5031663382 @default.
• W2059581639 hasAuthorship W2059581639A5034147174 @default.
• W2059581639 hasAuthorship W2059581639A5037630452 @default.
• W2059581639 hasAuthorship W2059581639A5039502897 @default.
• W2059581639 hasAuthorship W2059581639A5040155349 @default.
• W2059581639 hasAuthorship W2059581639A5040663056 @default.
• W2059581639 hasAuthorship W2059581639A5044738299 @default.
• W2059581639 hasAuthorship W2059581639A5046308082 @default.
• W2059581639 hasAuthorship W2059581639A5053631633 @default.
• W2059581639 hasAuthorship W2059581639A5065796888 @default.
• W2059581639 hasAuthorship W2059581639A5080149524 @default.
• W2059581639 hasAuthorship W2059581639A5080532811 @default.
• W2059581639 hasAuthorship W2059581639A5085895771 @default.

• next